Login to Your Account

Pharma: Clinic Roundup

Tuesday, March 27, 2012
• CSL Behring, of Charlotte, N.C., said the first patient was enrolled in the PATH (Polyneuropathy And Treatment with Hezentra) study to evaluate the safety and tolerability of two different doses of subcutaneous immunoglobulin compared to placebo in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription